During late embryogenesis and in the adult, blood vessels form primarily by angiogenesis, that is by sprouting from pre-existing vessels. Vascular endothelial growth factor (VEGF) potently promotes angiogenesis, and is indispensable for vascular development 1, 2 , and VEGFR-2 tyrosine kinase is the primary receptor transmitting VEGF signals in endothelial cells 3, 4 . VEGFR-3 is activated by the VEGF homologues VEGF-C and VEGF-D, which, when fully proteolytically processed, also stimulate VEGFR-2 (ref. 5 ) and induce the formation and activation of VEGFR-2-VEGFR-3 heterodimers 6, 7 . Inactivation of the Vegfr3 gene (also known as Flt4) leads to marked defects in arterial-venous remodelling of the primary vascular plexus, resulting in lethality by embryonic day (E) 10.5 (ref. 8) or to defective segmental artery morphogenesis 9 in mice or zebrafish, respectively. As the lymphatic vessels begin to develop at around E10.5, the level of Vegfr3 expression gradually decreases in the blood vessels, and from E16.5 onwards it is found nearly exclusively in the lymphatic vascular endothelium 10, 11 . However, VEGFR-3 is induced in angiogenic endothelial cells for example in tumours, wounds and in maturing a functional microcirculatory loop 22, 23 . The fusion of migrating tip cells is chaperoned by Tie2-and neuropilin-1-positive macrophages 24 , which express a variety of growth factors and proteolytic enzymes [24] [25] [26] . However, the molecular players regulating sprout fusion and vessel anastomosis have remained unknown.
We recently demonstrated that VEGFR-3 is expressed at a high level in endothelial tip cells, and that blocking VEGFR-3 with antibodies results in decreased angiogenesis during postnatal development and in tumours 14 . Stimulation of VEGFR-3 augments VEGF-induced angiogenesis and sustains blood vessel growth even in the presence of VEGFR-2 inhibitors, whereas antibodies against VEGFR-3 and VEGFR-2 in combination produce additive inhibition of angiogenesis and tumour growth 14 . Consistent with the concept of high levels of VEGFR-3 activity in the tip cells, genetic or pharmacological disruption of the Notch signalling pathway in vivo leads to widespread endothelial Vegfr3 expression and excessive sprouting 14, 27, 28 . Here, we show that genetic inactivation of Vegfr3 in endothelial cells surprisingly resulted in increased numbers of tip cells and vessel hyperplasia, which closely resembled loss of Notch signalling, whereas haploinsufficiency of Vegfc led to disruption of tip cell fusion points and inefficient angiogenesis. Our results implicate a bimodal role for VEGFR-3 in regulating angiogenesis, and indicate that the VEGF-C-VEGFR-3 signalling pathway controls the branching morphogenesis of blood vessels.
RESULTS

Endothelial deletion of Vegfr3 results in excessive angiogenesis
To study the consequences of homozygous endothelial-specific loss of Vegfr3 during angiogenesis, we mated Vegfr3 flox/flox mice with PdgfbiCreER T2 mice that express tamoxifen-activated Cre recombinase in endothelial cells 29 . Complete deletion of Vegfr3 in the retinal endothelium was achieved by 24 h following administration of 4-hydroxytamoxifen (4-OHT; Supplementary Fig. S1a-d) . Some residual Vegfr3 expression was detected by quantitative real-time (qRT) PCR ( Supplementary Fig. S1e ), presumably originating from retinal oligodendrocytes 30 or from monocytic cells 31 . Surprisingly, when Cre was induced in PdgfbiCreER T2 ; Vegfr3 flox/flox (Vegfr3 i∆EC ) mice for 48 h from postnatal day (P) 3 to P5, marked excessive branching, filopodia projection and hyperplasia of the nascent vascular plexus were observed ( Fig. 1a-e ). There was a significant increase in the proliferation of retinal endothelial cells ( Fig. 1f and Supplementary Fig. S2 ). Increased branching and vascular hyperplasia were also observed in hindbrains of Vegfr3 i∆EC embryos at E11.5
( Fig. 1g-k and Supplementary Fig. S3 ). We sought to validate these findings in other models outside the developing central nervous system. Excessive angiogenesis and sprouting were also detected in syngeneic subcutaneously implanted Lewis lung carcinomas (LLC) and B16-F10 melanomas in the Vegfr3 i∆EC mice (Fig. 1l ,m and data not shown). Furthermore, when ears of adult Vegfr3 i∆EC mice were transduced with AdVEGF, we observed a more robust angiogenic response, characterized by increased vascular tortuosity, enlargement and surface area ( Fig. 1n and Supplementary Fig. S4 ). VEGFR-3 tyrosine kinase activity is crucial for lymphatic vessel growth 32 , but its role in angiogenesis is not known. To determine whether VEGFR-3 is tyrosine phosphorylated in blood vascular endothelial cells in vivo, we injected recombinant VEGF, VEGF-C or BSA control protein into the outflow tract of wild-type embryos at E10.5, a stage when lymphatic vessels have not yet developed ( Fig. 2a-c) . VEGF did not promote tyrosine phosphorylation of VEGFR-3, unlike VEGF-C, but a faint phosphorylation signal was detected in both VEGF-and BSA-stimulated embryos, indicating a baseline level of VEGFR-3 phosphorylation (Fig. 2b) . As expected, VEGF and VEGF-C both stimulated VEGFR-2 phosphorylation (Fig. 2c) .
We have previously shown that VEGFR-3-blocking antibodies suppress angiogenesis 14 , whereas our results surprisingly showed that genetic targeting of Vegfr3 produced excessive angiogenic sprouting, indicating the possibility of ligand-independent sprouting. We found that VEGFR-3 was phosphorylated in the absence of its ligands by stimulation with collagen I in cultured human dermal blood vascular endothelial cells (hBECs) even in the presence of blocking monoclonal antibodies or a VEGFR tyrosine kinase inhibitor, whereas the Src inhibitor PP2 blocked collagen-I-induced phosphorylation of VEGFR-3 ( Fig. 2d) , indicating that VEGFR-3 can be phosphorylated independently of its ligands 33 . We addressed the role of VEGFR-3 kinase activity in angiogenesis in vivo by studying the retinas of Chy mice, which harbour a heterozygous kinase-inactivating point mutation in the tyrosine kinase domain (Vegfr3 KD/+ ), leading to a decreased level of (Fig. 3a,b) . In contrast, VEGFR-2-blocking antibodies rescued the increase in vascular area in the Vegfr3 i∆EC mice (Fig. 3a,b) . However, the nascent vessels appeared abnormally thick in the Vegfr3 i∆EC retinas following administration of VEGFR-2-blocking antibodies (arrowheads in Fig. 3a) , indicating that the phenotypic rescue was not complete. Furthermore, the expression level of VEGFR-1, a negative regulator of VEGF, was decreased in the Vegfr3 i∆EC retinas (Fig. 3c) , indicating an increased level of VEGF-VEGFR-2 signalling. Consistently, we detected a minor increase in the level of VEGFR-2 phosphorylation following stimulation of cultured human umbilical vein endothelial cells (HUVECs) with VEGF when VEGFR-3 expression was silenced using siRNA oligonucleotides (Fig. 3d) . Antibodies blocking human VEGFR-3 had no effect on VEGFR-2 phosphorylation in response to VEGF in HUVECs ( Supplementary Fig. S5a ). i ∆EC versus wild-type mice (see Supplementary Fig. S4) ; n = 3 ears per group. * * P < 0.005, * P < 0.05. Error bars, s.e.m. changes in Notch targets could be observed in pups treated with VEGFR-3-blocking antibodies ( Supplementary Fig. S5b ), indicating that the perturbations to VEGFR-3 by blocking antibodies and genetic targeting are qualitatively different.
Loss of Vegfr3 in endothelial cells leads to a decreased level of Notch target gene expression
To investigate the responsiveness of the Vegfr3-deficient endothelium to exogenous Notch activation, we administered Jagged1, a small peptide Notch agonist, to Vegfr3 i∆EC pups, and observed a rescue of the hypervascular phenotype (Fig. 4b,c) . Notably, the vasculature was normalized also in terms of morphology, unlike after anti-VEGFR-2 antibody administration (Fig. 4c) , indicating that decreased Notch signalling underlies the phenotype in Vegfr3 i∆EC retinas.
According to our results, VEGFR-3 contributes to the activation of Notch that is known to promote a phenotypic switch from a tip cell to a stalk cell. We chose to test this hypothesis in mosaic embryoid bodies consisting of both Vegfr3 +/LacZ heterozygous and wild-type embryonic stem cells 34 . Vegfr3 +/LacZ endothelial cells preferentially localized to the tips of VEGF-induced vascular sprouts (Fig. 4d,g ), whereas inhibiting Notch cleavage with the γ-secretase inhibitor DAPT abrogated the competitive advantage of the Vegfr3 +/LacZ endothelial cells (Fig. 4h) . Vegfr3 +/LacZ endothelial cells preferentially localized to the tips of vascular sprouts also in mosaic retinas at P5 (Fig. 4i) , indicating increased tip cell competence for the Vegfr3 haploinsufficient cells, which further implicates a decreased level of Notch signalling in endothelial cells with targeted Vegfr3 loss-of-function.
VEGF-C-VEGFR-3 signalling controls fusion of vascular sprouts
We next sought to determine which of the two VEGFR-3 ligands, VEGF-C or VEGF-D, is responsible for activating VEGFR-3 in the angiogenic endothelium in vivo. Strikingly, Vegfc heterozygous mice demonstrated retardation of retinal vascularization and decreased vessel branching density ( Fig. 5a-d ). In contrast, the Vegfc heterozygotes exhibited increased vessel sprouting and filopodia projection (Fig. 5e,f) , and a decrease in the level of Notch target gene expression (Fig. 5g) . These results implied a failure in stabilization of sprout fusion sites, and indicated that the excess sprouts represent failed tip cell fusions. Indeed, tracking endothelial cell migration paths by collagen IV immunostaining showed that endothelial cells in Vegfchaploinsufficient mice had frequently retracted from putative sprout fusion sites (Fig. 5h,i) . Importantly, Vegf (also known as Vegfa) levels in the Vegfc heterozygous retinas were normal, whereas Vegfc transcript levels were decreased by more than 50% ( Supplementary  Fig. S5c ). No changes in angiogenesis were observed in homozygous or heterozygous Vegfd gene-targeted retinas ( Supplementary Fig. S6 ), indicating that VEGF-C is the key ligand responsible for VEGFR-3 activation during retinal angiogenesis. Macrophages expressing Tie2 have been implicated as critical cellular chaperones for the formation of vascular anastomoses 24, 25 , and our results indicated a role for VEGF-C in this process. We detected VEGF-C expression in 50.9% (3.1% ± s.e.m.) of F4/80-positive macrophages in wild-type retinas. High-resolution imaging showed that all F4/80-and Tie2-positive cells were also VEGF-C positive (Fig. 5j) . Curiously, the VEGF-C-positive macrophages were positioned at the vascular front and primarily resided at vascular branching points immediately behind the tip cell front, whereas macrophages at sites of tip cell engagement expressed lower levels of VEGF-C ( Fig. 5j and Supplementary Fig. S7 ).
Interestingly, complete loss of macrophages in op/op mice 35 largely phenocopied heterozygous loss of Vegfc, as evidenced by decreased radial migration, area and branching of the vascular plexus, as well as by increased sprouting of the vessels (Fig. 5k-o) . Furthermore, the Notch target genes Hey1 and Hey2 were significantly downregulated in the op/op retinas (Fig. 5p) .
VEGF-C-VEGFR-3 signals induce Notch target genes through PI(3)K and FOXC2
To understand the mechanisms whereby VEGF-C-VEGFR-3 signalling contributes to Notch signalling, we stimulated cultured hBECs with VEGF-C and observed induction of Notch target genes over a 1-2 h stimulation period (Fig. 6a and data not shown) . We found that VEGF-C induced DLL4 in the hBECs ( Supplementary Fig. S8 ), but similar induction of the Notch targets was observed also in the presence of a soluble Notch inhibitor, Dll4-Fc (Fig. 6a) expression with siRNA suppressed the induction of Notch targets and DLL4 in response to VEGF-C (Fig. 6b) . Interestingly, VEGF-C potentiated Notch target gene expression induced by transduction of hBECs with a retrovirus encoding membrane-bound Dll4 (Fig. 6c) . The endothelial Notch receptors (NOTCH1 and NOTCH4) were not induced by VEGF-C stimulation (Supplementary Fig. S8 ). Taken together, these data indicate that VEGF-C-VEGFR-3 signalling can induce Notch target genes through a mechanism that is independent of canonical Notch signalling.
Phosphatidylinositol 3-kinase (PI(3)K) is a downstream effector of receptor tyrosine kinases, and it has been implicated as a positive regulator of Notch signalling [36] [37] [38] . PI(3)K is activated by VEGFR-3 signals, indicating a mechanism for activation of Notch downstream of VEGFR-3. Indeed, pharmacological inhibition of PI(3)K, but not the MAP-kinase MEK, suppressed Notch activation by VEGF-C (Fig. 6d and data not shown). Interestingly, siRNA silencing of VEGFR-3 expression returned ligand-induced activation of PI(3)K to baseline levels (Fig. 6e) , indicating that PI(3)K activity is at least partially regulated by VEGFR-3 in angiogenic endothelial cells. PI(3)K/Akt signalling is known to regulate FOX family transcription factors 39 , and VEGFR-3 has been reported to genetically interact with FoxC2 in lymphatic endothelial cells 40 . FOXC2 has also been shown to directly regulate HEY2 and DLL4 expression 38, 41 , indicating a possible link between the VEGFR-3 and Notch signalling pathways. We found FOXC2 messenger RNA induction in hBECs by VEGF-C stimulation, but not in response to Notch activation by membrane-bound Dll4 (Fig. 7a and data not shown) . Loss of Vegfr3 in vivo led to a marked decrease in the level of FoxC2 expression in the endothelial cells at the angiogenic front (Fig. 7b-d) . Downregulation of Foxc2 was also evident in Vegfc heterozygous retinas (Fig. 7e) . To investigate whether VEGFR-3 and FoxC2 function in the same pathway, we generated Vegfr3
+/− compound heterozygous mice, which exhibited similar excessive endothelial growth, branching and filopodia projection as observed in the Vegfr3 i∆EC homozygous retinas (Figs 7f-i,   1 ). The vasculature of single heterozygotes appeared indistinguishable from wild-type littermates (Fig. 7f-i) . Collectively, these data indicate that VEGFR-3 may induce Notch target genes through FoxC2 independently of Notch ligand-receptor interactions (Fig. 7j) .
DISCUSSION
Here we demonstrate that endothelial loss of VEGFR-3 leads to hypervascularization in developmental and tumour angiogenesis as well as in purely VEGF-driven angiogenesis. This finding contrasts with our previous data showing that VEGFR-3-blocking antibodies rather suppress angiogenesis 14, 42 . Although seemingly in stark conflict, it is important to consider that the two phenotypes are a result of profoundly different perturbations of VEGFR-3. In the case of antibodies, the intracellular domain is free to interact with intracellular proteins, whereas the entire receptor is missing following genetic deletion.
Indeed, VEGFR-3 can be phosphorylated by the intracellular tyrosine kinase Src, activated downstream of integrins following cell adhesion to matrix collagen I, even in conditions in which VEGFR-3 tyrosine kinase activity is lost 33 . Here we showed that the tyrosine kinase domain of VEGFR-3 can be phosphorylated following endothelial cell adhesion to collagen I in the presence of specific antibodies that block ligand-receptor interactions. Given that endothelial cells adhere to collagen I during angiogenic invasion of tissues 43 , it is likely that some phosphorylation of VEGFR-3 occurs also in vivo even in the presence of blocking antibodies or the absence of the ligand. Our analysis of mice harbouring various allelic combinations of endothelial-cell-deleted (i EC), kinase-dead mutant and wild-type Vegfr3 allowed for a titration of both kinase activity and genetic dose of VEGFR-3. The combination of a 50% decrease in genetic dose and loss of kinase activity in the remaining allele (i EC/KD) represented a threshold for the degree of VEGFR-3 phosphorylation required for normal angiogenesis. Importantly, our previous results indicate that the kinase-dead mutant may exert dominant-negative activity 32 , which is why it is likely not to precisely mimic the effect of VEGFR-3-blocking antibodies.
Our results indicate that VEGFR-3 controls Notch targets, but VEGFR-3 is also capable of inducing mitogenic signalling 14 . According to our model, the latter 'active' function is dependent on ligand binding and can be blocked by specific inhibitors, whereas the regulation of Notch can persist even in the presence of inhibitors (Fig. 7j) . The elucidation of the ligand-independent, or 'passive', signalling modality may explain why compound deletion of both VEGFR-3 ligands, Vegfc and Vegfd, does not recapitulate the early embryonic lethality of Vegfr3 genetargeted mice 17 , and why VEGFR-3-blocking antibodies, which prevent ligand-dependent activation of the receptor, suppress angiogenesis 14 . Interestingly, we observed a slight increase in the level of VEGFR-2 activity in cultured cells in which VEGFR-3 expression was silenced, whereas robust overexpression of wild-type, kinase-dead or ligand-binding-defective VEGFR-3 decreased the level of VEGFR-2 phosphorylation following VEGF stimulation 44 . Furthermore, we showed that VEGFR-2-blocking antibodies were able to rescue the hypervascularity resulting from endothelial deletion of Vegfr3, although morphologically the vessels remained abnormal. These findings indicate that VEGFR-3, although not capable of binding to VEGF, may act as a negative regulator of VEGF-VEGFR-2 signalling. Interestingly, implications towards such an interaction were already made in an elegant study demonstrating that VEGF can bring VEGFR-2 and VEGFR-3 to close proximity without inducing VEGFR-3 phosphorylation 45 . Importantly, we did not detect differences in the level of VEGFR-2 phosphorylation following VEGF stimulation in the presence of VEGFR-3-blocking antibodies.
The previous observations 45 place VEGFR-3 in VEGF-VEGFR-2 signalling clusters on the endothelial cell membrane and in subsequent signalosomes, which are known to contain multiple membranebound molecules that modulate the activity of VEGFRs, including ephrin-B2 (refs 46,47) 50 . It is therefore possible that VEGFR-3-blocking antibodies sterically disrupt the cluster or promote receptor internalization in addition to suppressing ligand-activated VEGFR-3 kinase activity. Conversely, loss of VEGFR-3 would allow its molecular partners to interact with VEGFR-2, which may modulate the signalling properties of this potent endothelial kinase.
We detected a significant decrease in the expression of multiple Notch target genes and the Notch ligand Dll4 in the Vegfr3 i∆EC retinas, and observed a rescue of the hypervascular phenotype following exogenous activation of the Notch signalling pathway. In contrast, VEGF-C was capable of inducing Notch target gene expression even in the presence of a potent Notch inhibitor, that is independently of the canonical Notch ligands, as well as potentiating the induction of Notch targets in response to Dll4-Notch interactions. Notch target gene induction stimulated by VEGF-C was suppressed by administration of a PI(3)K inhibitor, which has also been shown to suppress Notch target gene expression following stimulation with VEGF (refs 36,38) or cyclic adenosine monophosphate 37 (cAMP) in endothelial cells or endothelial cell progenitors, respectively.
We have previously established a genetic interaction for VEGFR-3 and FoxC2 in the regulation of lymphatic valve formation 40 ; Vegfr3 +/− compound heterozygous embryos exhibit increased lethality, whereas single heterozygotes survive in normal Mendelian ratios 51 . According to our findings and the published literature, it seems that VEGFR-3 can augment Notch signalling independently of canonical Notch ligand-receptor interactions through a mechanism involving FoxC2.
In zebrafish, VEGF-C controls angiogenesis before the formation of the lymphatic vascular system 52 . Interestingly, we detected induction of VEGF-C expression in macrophages at sites of sprout fusion, and robust expression in cells localized at vessel branch points. Tie2-positive macrophages have been implicated in tumour angiogenesis 53 and as chaperones of sprout fusion during development 24 , which is why it is of particular interest that the Tie2-positive macrophages were also VEGF-C positive. We observed similar vascular mispatterning, branching failure and a decreased level of Notch target gene expression in both Vegfc haploinsufficient mice and macrophage-deficient op/op mice. Although macrophages produce a plethora of growth factors 26 , our studies implicate VEGF-C as a key factor in vascular branch formation on the basis of genetic loss-of-function experiments, as well as the spatiotemporally coincident expression of both VEGF-C and VEGFR-3 at sites of sprout fusion.
Importantly, the phenotype resulting from heterozygous loss of Vegfc is different from homozygous endothelial deletion of Vegfr3, as characterized by decreased and increased branching, respectively. Deficiency of the ligand is likely to lead to decreased levels of activity of both VEGFR-3 and VEGFR-2, and to affect the 'active' mode of VEGFR-3 signalling, which promotes angiogenesis, whereas the passive mode of signalling is still able to function through intracellular activation of VEGFR-3. However, the loss of Vegfr3 abolishes both signalling modalities, leading to a significant decrease in the level of Notch signalling. Unlike the loss of VEGF-C, which resulted in reduced angiogenesis, the loss of VEGFR-3 did not negatively affect VEGFR-2 signalling; rather a small increase was observed.
VEGFR-3 signals seem to have an important role in a mechanism for the rapid conversion of tip cells to stalk cells, which is required at points of sprout fusion, where tip cells of opposing sprouts meet and establish cell-cell junctions. Our data support a model in which VEGF-C-producing macrophages stimulate VEGFR-3-positive tip cells to turn on Notch target genes, which leads to decreased sensitivity to VEGF and downregulation of VEGFR-3 in these cells 14, 27, 28 , facilitating the assembly of vascular loops. In support of this model, we observed FoxC2 expression only in stalk cells and in endothelial cells forming vascular loops, but not in tip cells. Interestingly, Vegfc expression is also found in angiogenic endothelial cells during development 14 , indicating the possibility of autocrine VEGF-C-VEGFR-3 interactions that may produce qualitatively distinct signals.
Our data indicate that BECs are instructed to migrate and proliferate primarily by VEGFR-2, whereas VEGFR-3 is the primary receptor driving differentiation signals towards the stalk-cell phenotype by activating Notch target gene expression through FoxC2. However, when VEGFR-2 is blocked, VEGFR-3 kinase activity can partially compensate for the loss of VEGFR-2 activity in driving the growth of endothelial cells, and vice versa 14 . Indeed, we have previously shown that VEGFR-3 activation can promote proliferation of BECs in vivo, but these signals are weak when compared with those originating from VEGFR-2 (refs 14,54). However, blocking VEGFR-3 augmented the effect of VEGF-VEGFR-2 axis inhibitors by providing additional inhibition of angiogenesis 14 , which reflects the capacity of VEGFR-3 for angiogenic signalling.
Our results using inducible gene targeting elucidate a bimodal function for VEGFR-3 in angiogenesis as a driver of both growth and differentiation of endothelial cells, which could not have been discovered by studying specific inhibitors alone, attesting to the power of mouse molecular genetics. VEGFR-3-blocking antibodies and kinase inhibitors are capable of targeting only the 'active' arm of VEGFR-3 signalling, whereas the 'passive' arm could be eliminated only by genetic deletion of the receptor (Fig. 7j) . Our results support an intricate mechanism that controls the formation and integrity of vascular micro-anastomoses during angiogenesis, and reinforce the concept of augmentation of Notch signals by receptor tyrosine kinase activation, which may provide additional tools for the therapeutic manipulation of the blood vascular system. Fig.  S1 ). The possibility of a 3 Vegfr3 mRNA fragment originating from a cryptic start codon was excluded by qRT-PCR probes targeting the 5 and 3 ends of the Vegfr3 transcript; no difference in expression levels was found (data not shown).
METHODS
Methods
Analysis of angiogenesis in the postnatal mouse retina and in the embryonic mouse hindbrain. Neonatal Pdgfb-iCreER
;ROSA26 -R or control mice were intragastrically injected with 2 µl of 4-OHT (Sigma) dissolved in 97% ethanol, on P3 and P4 using a 10 µl Hamilton syringe. A 12 h induction of Cre activity with 4-OHT during P5 was sufficient to result in Cre-activated β-galactosidase reporter expression in most endothelial cells of the developing retinal vasculature; the strongest signal was observed in the tip cells ( Supplementary Fig. S1a ), which express high levels of Pdgfb (ref. 18 ). Induction for 48 h resulted in robust Cre-dependent β-galactosidase activity in all endothelial cells ( Supplementary Fig. S1b ). For the antibody treatments, NMRI pups were subcutaneously injected with 50 mg kg −1 of anti-VEGFR-3 (mF4-31C1; ref. 57) or anti-VEGFR-2 (DC101; ref. 58) on P3 and P4. The small peptide mimetic of the Notch ligand Jagged1 (Jag1) or scrambled control peptide (SC-Jag1, Thermo Scientific) was dissolved in 50% dimethylsulphoxide and 50% sterile water, and administered subcutaneously at 10 mg kg −1 (refs 19,59 ) on P3 and P4 at 12 h intervals. To identify proliferating endothelial cells, the pups were given 0.2 mg of 5-bromo-2-deoxyuridine (BrdU) by intraperitoneal injections, 2 h before being killed. In all cases, the pups were killed on P5, and their eyes were collected for analysis. For hindbrain analysis, pregnant females were given 2.5 mg of 4-OHT dissolved in 40% ethanol and 60% sunflower seed oil (Sigma), using a feeding needle at E10.5 (for 24 h analysis) or E10.5 and E11.5 (for 48 h analysis). Embryos were collected on E11.5 or E12.5, and hindbrains were processed for whole-mount immunohistochemistry.
Transduction of the mouse ear skin with adenoviral gene transfer vectors.
Cre was induced at least 2 days in advance by subcutaneous implantation of sustained release pellets (21 days) containing tamoxifen (25 mg, Innovative Research). Adenoviruses encoding human VEGF 165 or VEGF-B 167 were injected intradermally into the ears of Pdgfb-iCreER T 2 ;Vegfr3 flox/flox mice. A total of 2 × 10 8 plaque-forming units of each virus were injected in a volume of 50 µl. The mice were perfusion-fixed 5 days after injection, and the ears were collected and processed for whole-mount analysis 60 , or immersed in OCT medium (Tissue Tek).
Tumour cell lines, xenografts and treatments. B16-F10-Luc2-G5 mouse melanoma or mouse LLC cells were maintained in DMEM, supplemented with 2 mM L-glutamine, penicillin (100 U ml −1 ), streptomycin (100 µg ml −1 ) and 10% fetal calf serum (Promo Cell). For B16-F10-Luc2-G5 cells, zeocin was added at a final concentration of 0.3 mg ml −1 as a selection marker. The B16 and LLC syngeneic grafts were made by injecting 2-4 × 10 6 cells into the subcutaneous space in the abdominal flank of Pdgfb-iCreER T 2 ; Vegfr3 flox/flox mice. Again, Cre was induced by subcutaneous implantation of the sustained tamoxifen-release pellets (25 mg, Innovative Research). cells were cultured for two passages without feeders, trypsinized, depleted of LIF, followed by mixing of wild-type (DsRed) and Vegfr3 +/LacZ cells in a 1:1 ratio and left in suspension (day 0). On day 4, embryoid bodies were embedded in a polymerized collagen I gel (as previously described 70 ) with the addition of 30 ng ml −1 mVEGF 164 (Peprotech) with dimethylsulphoxide or DAPT (5 µM, Sigma-Aldrich). Medium was changed on day 6 and every day thereafter.
qRT-PCR. Total RNA from retinas, collected at P5, or hBECs was isolated using the RNeasy Mini Kit (Qiagen) or the NucleoSpin RNA II Kit (Macherey-Nagel). Homogenization was carried out using rotor-stator homogenization, followed by oncolumn DNase digestion (RNase-Free DNase Set, 79254). Quality control of samples was carried out using a Nanodrop ND-1000 spectrophotometer. RNA was reversetranscribed using the DyNAmo cDNA Synthesis Kit (F-470L, Finnzymes) or the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's instructions. Three qRT-PCR reactions were carried out from every in vitro transcription reaction using TaqMan Gene Expression Assays (Applied Biosystems) and the DyNAmo Probe qPCR Kit (F-450S, Finnzymes) or the iQ Supermix Kit (Bio-Rad). qRT-PCR was carried out using a BIO-RAD C1000 Thermal cycler according to a standardized protocol. The TaqMan Gene Expression Assays used for mouse mRNA were:
and Foxc2 (Mm01250130_s1). At least three retinas from Pdgfb-iCreER T 2 ; Vegfr3 flox/flox and Vegfr3 flox/flox littermates were used for analysis at P5. The TaqMan Gene Expression Assays used for human RNA were: GAPDH (Hs99999905_m1), HEY1 (Hs01114113_m1), HEY2 (Hs00232622_m1), NRARP (Hs01104102_s1), DLL4 (Hs01117332_g1), NOTCH1 (Hs01062014_m1), NOTCH4 (Hs00965895_g1) and FOXC2 (Hs00270951_s1). The data were normalized to the endogenous controls Gapdh or Cadh5 and GAPDH in murine and human samples, respectively. At least three independent experiments per condition were analysed. Fold changes were calculated using the comparative CT (threshold cycle) method.
Vessel morphometry and quantitative analysis. The vascular surface area in retinas was quantified as an isolectin-B4-positive area from ×10 confocal micrographs acquired of all intact quarters of the processed retina and at a similar distance from the optic nerve using Image J software, as described previously 14 . PECAM-1-positive vessels from thick tumour sections were quantified from 1.69 mm 2 micrographs from regions of uniform staining intensity in a similar manner. PECAM-1-positive vessels in the ear sections were quantified from images that were acquired using tile-scanning mode with a pinhole diameter >3 Airy units. Vessel branching points, sprouts and filopodia number were counted manually from fluorescence micrographs of retinas, as described previously 71 . For each hindbrain, the number of sprouting vessels on the pial side and the number of branching points on the subventricular zone were determined in 3-6 randomly chosen 0.85 mm 2 fields. At least two litters of embryos per embryonic stage were independently analysed. Images were edited using PhotoShop software (Adobe).
Statistical analysis. Statistical analysis was carried out using PASW Statistics 18.0.
A two-tailed Student t -test, paired Student t -test or one-way analysis of variance (ANOVA) was used for statistical analysis. A P value of less than 0.05 was considered to be statistically significant.
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Figure S1 Figure S8 VEGF-C induces DLL4 in hBECs. Fold changes in DLL4, NOTCH1 and NOTCH4 mRNA levels analyzed by RT-qPCR, in nonconfluent hBECs stimulated with VEGF (100 ng ml -1 ) or VEGF-C (100 ng ml -1 ) for 1 or 2 hours after starvation. GAPDH was used as normalization control. *P < 0.05; n = 3 plates/group. Error bars = S.E.M. 
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